Business Wire

“Genome Editing: The Next Frontier”: 4th Conference in the Bridging Biomedical Worlds Series

Del

The Fondation IPSEN today announced the fourth Bridging Biomedical Worlds Conference, “Genome Editing: The Next Frontier”, which will be focused on the improvement and most recent applications of genome editing tools. This meeting will take place in Singapore from February 5 th to 7 th 2018.

The Significance of Genome Editing

For decades, scientists have searched for a genome editing tool that will facilitate the easy and sustainable modification of genes in health and biomedical research. The engineering of CRISPR-Cas9 five years ago proved to be a breakthrough in the field. CRISPR-Cas9 is a natural defense system in bacteria that has been modified to allow any DNA modification in all living species. CRISPR-Cas9 technology has opened up promising avenues in various scientific fields, and is being utilized in the development of innovative therapies for cancer and other infectious and genetic diseases.

The 2018 Bridging Biomedical Worlds Conference, “Genome Editing: The Next Frontier”, will be held in Singapore from February 5th to 7th 2018. Feature a line-up of internationally renowned speakers who are experts in their fields, the Conference will cover a range of topics including natural bacterial immune mechanisms, the next generation of genome editing tools, and applications of genome editing tools in scientific discovery and in therapy.

This event is jointly organized by Fondation IPSEN, AAAS/Science, AAAS/Science Translational Medicine, and A*STAR’s Institute of Molecular and Cell Biology (IMCB).

Program

     

Keynote Lecture

Engineering Smarter T-cells

Carl JUNE
 

Session I

CRISPRs for Attack and Defense

Avec Dipali SASHITAL, Rotem SOREK, Seokjoong KIM
 

Session II

Advances in Genome Editing

Avec Nicole GAUDELLI, Martin JINEK, Farren ISAACS, Gene YEO, Fabrice VANDEPUT
 

Session III

CRISPRs as a Discovery Tool

Avec Mashito IKAWA, Neville SANJANA, David BIKARD
 

Session IV

Table ronde : Scientific Challenges for Genome Editing

 

Session V

Therapeutic Applications of Gene Editing

Avec Suk See DE RAVIN, Paula CANNON, Eric OLSON, Waseem QASIM, Andrea CRISANTI
 

Session VI

Table ronde : Therapeutic Challenges for Genome Editing

 

Keynote Lecture

Functional Genomics to Study Cancer

David SABATINI

This scientific meeting has been recognized “INNOVATION YEAR 2018” by the French Singapore Embassy. This label has been launched in 2017 by Mister François Hollande, former President of the French Republic, and Lee Hsien Loong, Singapore prime minister, to reinforce bilateral initiatives and collaboration in key sectors like health or biotechnology.

Detailed program: https://www.bridgingbiomedicalworlds.com

To RSVP for the Conference, please contact: yannick.tanguy@ipsen.com

About the Bridging Biomedical Worlds series

The Fondation IPSEN and the American Association for the Advancement of Science launched a new Conference series in 2014 entitled “Bridging Biomedical Worlds” to facilitate the global exchange of knowledge about important advances in key research areas, and boost communication and cooperation among researchers, clinicians, and industry scientists from East and West. Each year a ground-breaking topic is tackled with a local partner in a different country in Asia.

More info on the previous meetings: https://www.bridgingbiomedicalworlds.com/previous-edition/

About A*STAR’s Institute of Molecular and Cell Biology (IMCB)

The Institute of Molecular and Cell Biology (IMCB) was launched on 23 January 1985, with its official opening ceremony held on 2 October 1987 at the National University of Singapore (NUS). It subsequently became an autonomous research institute (RI) of A*STAR, moving to Biopolis in 2004. IMCB’s vision is to be a premier cell and molecular biology institute which addresses the mechanistic basis of human diseases and its mission is to conduct cutting-edge discovery research in disease pathways; to groom early career researchers to be future leaders in research; and to collaborate with medical and industry communities for research impact. IMCB plays an important role training and recruiting scientific talents, and has contributed to the development of other research entities in Singapore. Its success in fostering a biomedical research culture in Singapore has catalysed Singapore’s transformation into an international hub for biomedical research, development and innovation.

Funded primarily by the Biomedical Research Council (BMRC) of A*STAR, IMCB’s Discovery research comprises 5 major programmes: Cancer Cell Signalling, Multi-Modal Molecular (M3) Biology, Epigenetics and Diseases, iPS cell and Regenerative Medicine, and Technology and Translation. IMCB’s technologies and platforms focus on Genome-wide RNAi, Humanized Mouse Models, Proteomics and Protein Engineering, Gene Therapy and Gene Editing, and Molecular Histopathology.

IMCB strives to maintain the scientific excellence of PI-driven research and at the same time aims to promote collaborative team-based projects of medical and industrial relevance.

For more information about IMCB, visit www.imcb.a-star.edu.sg.

About AAAS/Science

The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science (www.sciencemag.org) as well as Science Translational Medicine (www.sciencetranslationalmedicine.org), Science Signaling (www.sciencesignaling.org), and Science Advances (http://advances.sciencemag.org/). AAAS was founded in 1848, and includes some 261 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million. The non-profit AAAS (www.aaas.org) is open to all and fulfills its mission to “advance science and serve society” not only by publishing the very best scientific research but also through initiatives in science policy, international programs and science education.
www.sciencemag.org

About AAAS/Science Translational Medicine

Science Translational Medicine was launched in October 2009. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest biomedical research findings from basic, translational, and clinical researchers from all established and emerging disciplines relevant to medicine. Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. This paradox illustrates the daunting complexity of the challenges faced by translational researchers as they apply the basic discoveries and experimental approaches of modern science to the alleviation of human suffering. A major goal of Science Translational Medicine is to publish papers that identify and fill the scientific knowledge gaps at the junction of basic research and medical application in order to accelerate the translation of scientific knowledge into new methods for preventing, diagnosing and treating human disease.
www.sciencetranslationalmedicine.org

The Fondation IPSEN

Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche. Moreover, the Fondation IPSEN has created several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the scientific journals Cell and Science. The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants.
www.fondation-ipsen.org

Contact information

For further information, and to RSVP for the Conference:
Fondation IPSEN
Yannick TANGUY, Tel: +33 (0)6 81187860
E-mail: yannick.tanguy@ipsen.com
www.fondation-ipsen.org
Twitter: @FondationIpsen (#BridgBioWorlds)
LinkedIn: Fondation IPSEN
YouTube: Fondation IPSEN video

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IFF’s Frutarom Division Completes Acquisition of 60% of Thailand-based Mighty18.1.2019 12:50Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), announced that its Frutarom Division has completed the acquisition of 60% of the share capital of The Mighty CO. LTD. (“Mighty”), a leading savory solutions provider in Thailand, thus continuing its growth strategy in Southeast Asia. Amos Anatot, President of IFF's Frutarom Division, said, “The completion of this deal with Mighty underscores that the Frutarom division will continue on its growth strategy and pursue attractive companies that create new opportunities or build on current capabilities.” Mr. Anatot continued, “And in this case, we are helping to grow our capabilities in savory solutions – already an area of strength for legacy Frutarom, now IFF." Mighty, founded in 1989, develops, produces and markets reaction flavors, with particular expertise in savory solutions. The company’s portfolio includes flavors, seasoning blends, marinades, and specialty functional raw materials f

LTI Q3 FY19: Constant currency revenue growth up 6.1% QoQ and 20.6% YoY; Net Profit jumps 32.8% YoY18.1.2019 12:02Pressemelding

Larsen & Toubro Infotech (BSE code: 540005, NSE: LTI), a global technology consulting and digital solutions company, announced its Q3 FY19 results today. In US Dollars: Revenue at USD 346.9 million; growth of 5.6% QoQ and 18.2% YoY Constant Currency Revenue growth of 6.1% QoQ and 20.6% YoY In Indian Rupees: Revenue at Rs 24,729 million; growth of 6.1% QoQ and 31.3% YoY Net Income at Rs 3,755 million; growth of (6.2%) QoQ and 32.8% YoY “We are pleased to deliver another strong quarter with 5.6% QoQ growth in USD revenues. Our broad-based revenue growth, superior margin delivery and steady cash generation in Q3 is a testimony of our focused execution and client centricity. We are also thrilled to welcome Ruletronics to LTI family. Ruletronics enables businesses to transform and evolve digitally by providing innovative BPM and CRM solutions leveraging Pega Platform.” - Sanjay Jalona, Chief Executive Officer & Managing Director, LTI Recent Deal Wins Nets, the leading payments company in th

Schlumberger Announces Full-Year and Fourth-Quarter 2018 Results18.1.2019 12:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for full-year 2018 and the fourth quarter of 2018. (Stated in millions, except per share amounts) Full-Year Results Twelve Months Ended Change Dec. 31, 2018 Dec. 31, 2017 Year-on-year Revenue $32,815 $30,440 8% Pretax operating income $4,187 $3,921 7% Pretax operating margin 12.8% 12.9% -12 bps Net income (loss) - GAAP basis $2,138 $(1,505) n/m Net income, excluding charges & credits* $2,261 $2,085 8% Diluted EPS (loss per share) - GAAP basis $1.53 $(1.08) n/m Diluted EPS, excluding charges and credits* $1.62 $1.50 8% Full-Year Consolidated Revenue by Area North America $11,984 $9,487 26% Latin America 3,745 3,976 -6% Europe/CIS/Africa 7,158 7,072 1% Middle East & Asia 9,543 9,394 2% Other 385 511 n/m $32,815 $30,440 8% North America revenue $11,984 $9,487 26% International revenue $20,446 $20,442 - North America revenue, excluding Cameron $9,668 $7,518 29% International revenue, excluding Cameron $17,675 $17,423 1% *These are non

FLIR Systems Awarded $89 Million Contract from French Armed Forces to Deliver Black Hornet Personal Reconnaissance System18.1.2019 11:00Pressemelding

FLIR Systems, Inc. (NASDAQ: FLIR) announced today it has been awarded a contract from the French Defense Procurement Agency (DGA) in support of the French Operational Pocket Drone (DrOP) program. The contract has a ceiling value of $89 million to provide the FLIR Black Hornet® 3 nano-unmanned aerial vehicle (UAV) and Personal Reconnaissance System (PRS) to support French Armed Forces operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190118005085/en/ The French Armed Forces awarded FLIR Systems a contract to deliver the Black Hornet Personal Reconnaissance System for military operations. (Photo: Business Wire) The Black Hornet PRS is the world’s smallest combat-proven nano-Unmanned Aerial System (UAS) and is currently deployed in more than 30 countries. The Black Hornet enables the warfighter to maintain situational awareness, threat detection, and surveillance no matter where the mission takes them. Equipped with el

ISAE-SUPAERO Launches a New MOOC in the Field of Space and Aeronautics18.1.2019 08:00Pressemelding

ISAE-SUPAERO, the world leader in aerospace engineering training has launched a new MOOC for the start of 2019: "DynaMOOC". “DynaMOOC”: understand and apply the fundamentals of structural dynamics The basic architecture of aerospace structures is generally founded on static criteria. The modern approach consists of integrating the dynamics not to certification but also to the fundamental design and specification of aerospace structures and light structures. Thus, all areas which involve structural works are affected: aircraft, vehicles, naval engineering and civil engineering. In-depth knowledge of the fundamentals of dynamics offers a new perspective on the classification and behavior of all mechanical systems. This MOOC goes back to the basics of solid dynamics applied to structural analysis. This four-week course is aimed at undergraduate students in mechanical or physical engineering who would like to comprehend the transition from statics to dynamics, as well as to structural engi

Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief18.1.2019 06:30Pressemelding

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190117005697/en/ Carenity Infographic Ipsen (Euronext: IPN; ADR: IPSEY) today presents at TOXINS, results from an international survey revealing the hidden burden of spasticity and the need for longer periods of symptomatic relief1. Affecting 12 million people around the world2, spasticity is one of the most common and disabling conditions associated with neurological diseases in adults (stroke, traumatic brain, etc.) and characterised by an abnormal increase in muscle tone or stiffness3. A survey of 615 respondents from 6 participating countries confirms that spasticity has a profound impact on ability to perform everyday tasks, including the ability to carry items, walk, and drive and reduces independence overall. The survey1 also found that spasticity affects the ability to work (22% of patients surveyed did not work) and impacts sex life as well as self-este